Neurology and Neurosurgery - Global Neurology Academy

Episodes 193-208 of 354

Alzheimer’s Research: Opening the Blood-Brain Barrier with Aducanumab and Focused Ultrasound
Alzheimer’s Research: Opening the Blood-Brain Barrier with Aducanumab and Focused Ultrasound
NeuroFrontiers
Alzheimer’s Research: Opening the Blood-Brain Barrier with Aducanumab and Focused Ultrasound
- Andrew Wilner, MD, FACP, FAAN
- Marc Haut, PhD
First Episode Psychosis: Improving Patient Outcomes Through Early Intervention
First Episode Psychosis: Improving Patient Outcomes Through Early Intervention
NeuroFrontiers
First Episode Psychosis: Improving Patient Outcomes Through Early Intervention
- Ashley Baker, MSN, PMHNP
- Hannah Brown, MD
Investigating the Clinical Utility of the Multiple Sclerosis Disease Activity Test
Investigating the Clinical Utility of the Multiple Sclerosis Disease Activity Test
NeuroFrontiers
Investigating the Clinical Utility of the Multiple Sclerosis Disease Activity Test
- Andrew Wilner, MD, FACP, FAAN
- William A. Kilgo, MD
Adverse Childhood and Lifespan Stressors Take a Toll on MS Disease Severity
Adverse Childhood and Lifespan Stressors Take a Toll on MS Disease Severity
NeuroFrontiers
Adverse Childhood and Lifespan Stressors Take a Toll on MS Disease Severity
- Andrew Wilner, MD, FACP, FAAN
- Carri Polick, PhD, RN
MS in Black and Hispanic Patients: Examining Prevalence and Disease Characteristics
MS in Black and Hispanic Patients: Examining Prevalence and Disease Characteristics
NeuroFrontiers
MS in Black and Hispanic Patients: Examining Prevalence and Disease Characteristics
- Jennifer Caudle, DO
- Mitzi Joi Williams, MD
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
NeuroFrontiers
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
- Charles Turck, PharmD, BCPS, BCCCP
- Anibal Chertcoff, MD
Examining Emerging Gut Microbiota Biomarkers for MS
Examining Emerging Gut Microbiota Biomarkers for MS
NeuroFrontiers
Examining Emerging Gut Microbiota Biomarkers for MS
MS in Children: Exploring Biomarker Research Advancements
MS in Children: Exploring Biomarker Research Advancements
NeuroFrontiers
MS in Children: Exploring Biomarker Research Advancements
- Ahmed Abdelhak, MD
New Consensus for Smoldering Disease in MS
New Consensus for Smoldering Disease in MS
NeuroFrontiers
New Consensus for Smoldering Disease in MS
Discussing Disparities in MS Care for Underrepresented Populations
Discussing Disparities in MS Care for Underrepresented Populations
NeuroFrontiers
Discussing Disparities in MS Care for Underrepresented Populations
- Charles Turck, PharmD, BCPS, BCCCP
- Tirisham V. Gyang, MD
- Gopika Govindan Kutty, MD
An Overview of MS Biomarkers
An Overview of MS Biomarkers
NeuroFrontiers
An Overview of MS Biomarkers
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
NeuroFrontiers
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
- Charles Turck, PharmD, BCPS, BCCCP
- Jay Avasarala, MD, PhD
Highlights from the 2023 Psych Congress
Highlights from the 2023 Psych Congress
NeuroFrontiers
Highlights from the 2023 Psych Congress
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Craig Chepke, MD, FAPA
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
NeuroFrontiers
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
Diagnosing Suspected MS: A Review of the Updated Guidelines
Diagnosing Suspected MS: A Review of the Updated Guidelines
NeuroFrontiers
Diagnosing Suspected MS: A Review of the Updated Guidelines
- Andrew Wilner, MD, FACP, FAAN
- Eoin Flanagan, MB, BCh
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
NeuroFrontiers
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care

13/11